MCID: LNG031
MIFTS: 51

Lung Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm 12 15
Lung Neoplasms 43 71
Tumor of the Lung 12
Lung Tumor 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3683
MeSH 43 D008175
NCIt 49 C3200
UMLS 71 C0024121

Summaries for Lung Benign Neoplasm

MalaCards based summary : Lung Benign Neoplasm, also known as lung neoplasms, is related to rhabdomyosarcoma 2 and lung adenoma, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Ipratropium and Terbutaline have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 881)
# Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 2 32.0 TP53 SYP ENO2
2 lung adenoma 31.8 TP53 SFTPC SCGB1A1 RARB KRAS HRAS
3 bronchus cancer 31.5 GRP FHIT ENO2
4 granular cell tumor 31.0 SYP NKX2-1 ENO2
5 angiosarcoma 30.8 TP53 KRT7 KRAS
6 perivascular epithelioid cell tumor 30.6 SYP NKX2-1 CDKN2A
7 thyroid carcinoma 30.6 TP53 NKX2-1 HRAS
8 glomus tumor 30.6 TP53 SYP ENO2 CDKN2A
9 histiocytoma 30.6 TP53 ENO2 CDKN2A
10 exanthem 30.5 KRAS HRAS EGFR
11 alveoli adenoma 30.4 SFTPC SCGB1A1 NKX2-1
12 carcinoid tumors, intestinal 30.4 SYP NKX2-1 ENO2 CHGA
13 glomangiosarcoma 30.4 TP53 SYP
14 in situ carcinoma 30.4 TP53 HRAS EGFR CDKN2A
15 epithelial-myoepithelial carcinoma 30.4 TP53 KRT7 HRAS
16 myoepithelial carcinoma 30.4 TP53 KRT7 HRAS
17 pulmonary sclerosing hemangioma 30.4 SYP NKX2-1 KRT7 ENO2 CHGA
18 malignant peripheral nerve sheath tumor 30.3 TP53 KRT7 EGFR CDKN2A
19 mucoepidermoid carcinoma 30.3 TP53 NKX2-1 KRT7 EGFR CHGA CDKN2A
20 pleural cancer 30.3 TP53 EGFR CDKN2A
21 sclerosing hemangioma 30.3 SYP NKX2-1 KRT7 ENO2 CHGA
22 appendix adenocarcinoma 30.3 SYP KRT7 KRT20 KRAS HRAS
23 rhabdoid cancer 30.3 TP53 SYP ENO2 CDKN2A
24 epithelioid sarcoma 30.3 SYP KRT7 EGFR
25 pleomorphic rhabdomyosarcoma 30.3 TP53 SYP KRT7
26 papillary adenocarcinoma 30.3 TP53 NKX2-1 KRT7 KRAS
27 vascular cancer 30.3 TP53 SYP KRT7
28 bronchial neoplasm 30.2 SFTPC SCGB1A1 NKX2-1
29 carcinosarcoma 30.2 TP53 KRT7 KRAS HRAS EGFR
30 neurofibromatosis, type iv, of riccardi 30.2 TP53 KRAS HRAS
31 oncocytoma 30.2 SYP NKX2-1 KRT7 KRT20
32 malignant pleural mesothelioma 30.2 TP53 NKX2-1 EGFR CDKN2A
33 hemangioma 30.2 TP53 SYP NKX2-1 KRT7 KRAS ENO2
34 sertoli-leydig cell tumor 30.2 SYP KRT7 ENO2
35 esophagus adenocarcinoma 30.2 TP53 EGFR CDKN2A
36 adenocarcinoma in situ 30.2 KRT7 KRT20 KRAS EGFR CDKN2A
37 thyroid tumor 30.2 TP53 KRAS HRAS
38 tuberous sclerosis 30.2 TP53 SYP ENO2 CHGA
39 carcinoid syndrome 30.1 SYP ENO2 CHGA
40 esophagitis 30.1 TP53 EGFR CDKN2A
41 adenocarcinoma 30.1 TP53 NKX2-1 KRT7 KRT20 KRAS HRAS
42 familial adenomatous polyposis 30.1 TP53 MGMT KRAS HRAS
43 lung oat cell carcinoma 30.1 SYP GRP ENO2 CHGA
44 lymphoepithelioma-like thymic carcinoma 30.1 SYP NCAM1 CDKN2A
45 large cell neuroendocrine carcinoma 30.1 SYP NKX2-1 NCAM1 KRT7 KRT20 ENO2
46 neuroendocrine carcinoma 30.1 SYP NKX2-1 NCAM1 KRT7 KRT20 GRP
47 pleomorphic adenoma 30.1 TP53 KRT7 HRAS CDKN2A
48 lymphoepithelioma-like carcinoma 30.1 KRT7 KRT20 ENO2
49 pulmonary large cell neuroendocrine carcinoma 30.1 SYP NCAM1 CHGA
50 lung disease 30.1 TP53 SFTPC SCGB1A1 NKX2-1 GRP ENO2

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:



Diseases related to Lung Benign Neoplasm

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:


hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.91 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00106-A-0 9.91 KRAS
3 Decreased viability GR00221-A-1 9.91 EGFR HRAS KRAS
4 Decreased viability GR00221-A-2 9.91 HRAS KRAS
5 Decreased viability GR00221-A-3 9.91 HRAS
6 Decreased viability GR00221-A-4 9.91 EGFR
7 Decreased viability GR00301-A 9.91 KRAS
8 Decreased viability GR00381-A-1 9.91 KRAS
9 Decreased viability GR00402-S-2 9.91 EGFR HRAS KRAS NCAM1
10 Reduced mammosphere formation GR00396-S 9.23 CHGA EGFR HRAS KRAS KRT7 NCAM1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 CDKN2A EGFR ENO2 KRAS KRT7 NCAM1
2 homeostasis/metabolism MP:0005376 10.25 CDKN2A CHGA EGFR FHIT HRAS KRAS
3 mortality/aging MP:0010768 10.25 CDKN2A CHGA EGFR FHIT HRAS KRAS
4 growth/size/body region MP:0005378 10.23 CDKN2A CHGA EGFR ENO2 HRAS KRAS
5 cardiovascular system MP:0005385 10.22 CDKN2A CHGA EGFR HRAS KRAS NKX2-1
6 endocrine/exocrine gland MP:0005379 10.22 CDKN2A CHGA EGFR HRAS KRAS MGMT
7 digestive/alimentary MP:0005381 10.15 CDKN2A EGFR FHIT HRAS KRAS NKX2-1
8 neoplasm MP:0002006 10.15 CDKN2A EGFR FHIT HRAS KRAS MGMT
9 nervous system MP:0003631 10.13 CDKN2A CHGA EGFR ENO2 GRP HRAS
10 no phenotypic analysis MP:0003012 9.91 CDKN2A CHGA EGFR HRAS KRAS MGMT
11 normal MP:0002873 9.81 EGFR HRAS KRAS NKX2-1 RARB RASSF1
12 renal/urinary system MP:0005367 9.56 CHGA EGFR HRAS KRAS KRT7 RARB
13 respiratory system MP:0005388 9.36 CDKN2A EGFR ENO2 HRAS KRAS MGMT

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 741)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
2
Terbutaline Approved Phase 4 23031-25-6 5403
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
4
Dalteparin Approved Phase 4 9005-49-6
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
7
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
8
Remifentanil Approved Phase 4 132875-61-7 60815
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Tropisetron Approved, Investigational Phase 4 89565-68-4, 105826-92-4 5595
11
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
12
Desflurane Approved Phase 4 57041-67-5 42113
13
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
16
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
19
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
20
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
21 Adrenergic alpha-2 Receptor Agonists Phase 4
22 Opiate Alkaloids Phase 4
23 Heparin, Low-Molecular-Weight Phase 4
24 calcium heparin Phase 4
25 Excitatory Amino Acid Antagonists Phase 4
26 Excitatory Amino Acids Phase 4
27 Anesthetics, Dissociative Phase 4
28 Anesthetics, Intravenous Phase 4
29 Free Radical Scavengers Phase 4
30 Diphosphonates Phase 4
31 N-Methylaspartate Phase 4
32
Bilirubin Phase 4 69853-43-6, 635-65-4 21252250 5280352
33 Antidotes Phase 4
34 N-monoacetylcystine Phase 4
35 Anesthetics, Inhalation Phase 4
36 Serotonin Agents Phase 4
37 Serotonin Antagonists Phase 4
38 Serotonin 5-HT3 Receptor Antagonists Phase 4
39 Serotonin Uptake Inhibitors Phase 4
40 Antipsychotic Agents Phase 4
41 Narcotics Phase 4
42 Antibodies Phase 4
43 Immunoglobulins Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Hormones Phase 4
46 Hormone Antagonists Phase 4
47
Apatinib Phase 4 811803-05-1
48 Antineoplastic Agents, Hormonal Phase 4
49 glucocorticoids Phase 4
50 Ibandronic Acid Phase 4

Interventional clinical trials:

(show top 50) (show all 4883)
# Name Status NCT ID Phase Drugs
1 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
2 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
3 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
4 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
5 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
6 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
7 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
8 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
9 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
10 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
11 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
12 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
13 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
14 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
15 A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain Completed NCT01783236 Phase 4 IV Acetaminophen;Saline Placebo
16 A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients Completed NCT02744664 Phase 4 Icotinib
17 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
18 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
19 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
20 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
21 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
22 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
23 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
24 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
25 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
26 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
27 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
28 Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer. Completed NCT00925444 Phase 4
29 Effects of Different Doses of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction of Patients After Radical Resection of Lung Cancer by Thoracoscope Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
30 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
31 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
32 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
33 A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
34 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
35 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
36 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
37 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
38 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
39 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
40 Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients Completed NCT01060137 Phase 4 fentanyl matrix
41 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
42 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
43 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
44 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
45 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
46 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
47 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
48 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
49 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
50 Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carboplatin
Carmustine
Cholecalciferol
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
Procarbazine
Procarbazine Hydrochloride
Teniposide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Genetic Tests for Lung Benign Neoplasm

Anatomical Context for Lung Benign Neoplasm

MalaCards organs/tissues related to Lung Benign Neoplasm:

40
Lung, Brain, Testes, Breast, T Cells, Lymph Node, Bone

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 1154)
# Title Authors PMID Year
1
GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. 54 61
19620839 2009
2
Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. 61 54
16395694 2007
3
Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. 61 54
16506596 2006
4
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. 54 61
15547185 2004
5
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. 54 61
15084379 2004
6
Dysregulated secretoglobin expression in human lung cancers. 61 54
12826312 2003
7
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. 61 54
12652739 2003
8
Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. 54 61
10987260 2000
9
Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. 61 54
9476905 1998
10
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. 61 54
8638091 1996
11
Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. 61 54
7545909 1994
12
Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. 54 61
1313613 1992
13
[Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms]. 61 54
1843646 1991
14
Lung cancer metastasis to the breast mimicking inflammatory breast carcinoma on imaging. 61
31660096 2019
15
Pulmonary carcinoid presenting with persistent pneumothorax. 61
31712234 2019
16
Psychosocial interventions for informal caregivers of lung cancer patients: A systematic review. 61
31701588 2019
17
CT-based radiomics for prediction of histologic subtype and metastatic disease in primary malignant lung neoplasms. 61
31722085 2019
18
Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review. 61
31739404 2019
19
Predicting miRNA-Disease Associations by Incorporating Projections in Low-Dimensional Space and Local Topological Information. 61
31500152 2019
20
Incidental endobronchial hamartoma in a patient with enchondroma. 61
31527201 2019
21
Left Lung Neoplasms and Bilateral Pleural Effusion Combined Elevated Carcinoembryonic Antigen in Pleural Effusion with Negative Result of Thoracoscopy Pleural Biopsy Misdiagnosed as Lung Carcinoma Ultimately Confirmed Pulmonary Sarcomatoid Carcinoma by CT-guided Percutaneous Lung Biopsy: a Case Report and Literature Review. 61
31414757 2019
22
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors. 61
31378896 2019
23
Embolization of Chest Neoplasms: The Next Frontier in Interventional Oncology? 61
31435125 2019
24
[Fluorescence Guided Sublobar Lung Resection by Using Three-dimensional Image Analysis and Transbronchial Instillation of Indocyanine Green]. 61
31296801 2019
25
MAMDA: Inferring microRNA-Disease associations with manifold alignment. 61
31154259 2019
26
Primary Pulmonary Involvement in Mucosa-associated Lymphoid Tissue Lymphoma. 61
31523541 2019
27
Prediction of Potential Disease-Associated MicroRNAs by Using Neural Networks. 61
31077936 2019
28
Surgical Treatment of Bilateral Lung Cancers: Long-Term Outcomes and Prognostic Factors. 61
30991418 2019
29
Bronchial Carcinoid Tumors with Massive Osseous Metaplasia: A Case Report and Review of the Literature. 61
30977863 2019
30
An integrated framework for the identification of potential miRNA-disease association based on novel negative samples extraction strategy. 61
30646823 2019
31
Inferring microRNA-disease association by hybrid recommendation algorithm and unbalanced bi-random walk on heterogeneous network. 61
30792474 2019
32
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. 61
31824199 2019
33
Spontaneous Partial Regression of a Carcinoid Tumor: Radiology May Not Capture the Real Picture. 61
30958990 2019
34
Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. 61
30154579 2019
35
A Rare Case of Primary Pulmonary Anaplastic Large Cell Lymphoma. 61
31583219 2019
36
Metachronous Pulmonary Neoplasms in Lung Transplantation-When They Arise in the Donor Lung: A Case Report. 61
30577319 2018
37
Novel Human miRNA-Disease Association Inference Based on Random Forest. 61
30439645 2018
38
Prediction of potential disease-associated microRNAs by composite network based inference. 61
30361693 2018
39
Inferring disease-associated microRNAs in heterogeneous networks with node attributes. 61
30281474 2018
40
Diagnosis of Multiple Primary Intestinal-Type Adenocarcinoma in the Lung by 18F-FDG PET/CT. 61
30004935 2018
41
CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. 61
30032841 2018
42
MDHGI: Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction. 61
30142158 2018
43
A Smooth Esophageal Stricture Causing Dysphagia. 61
29637299 2018
44
Clinical and Histopathologic Correlates and Management Strategies for Inflammatory Myofibroblastic tumor of the lung. A case series and review of the literature. 61
29869302 2018
45
Paraneoplastic limbic encephalitis associated with lung cancer. 61
29717222 2018
46
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. 61
29360191 2018
47
Advances on systemic treatment for lung neuroendocrine neoplasms. 61
29862235 2018
48
Management of acquired bronchopleural fistula due to chemical pneumonia. 61
29875593 2018
49
Prediction of microRNA-disease associations based on distance correlation set. 61
29665774 2018
50
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. 61
29455666 2018

Variations for Lung Benign Neoplasm

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1 12.58 TP53 RASSF1 RARB NQO1 KRAS HRAS
2
Show member pathways
12.53 TP53 RARB NQO1 KRAS HRAS EGFR
3
Show member pathways
12.4 TP53 KRAS HRAS EGFR
4 12.37 TP53 RASSF1 KRAS HRAS EGFR CDKN2A
5
Show member pathways
12.35 TP53 RASSF1 RARB KRAS HRAS FHIT
6 12.24 TP53 KRAS HRAS CDKN2A
7 12.19 TP53 KRAS HRAS EGFR
8 12.18 TP53 KRAS HRAS CDKN2A
9 12.05 TP53 KRAS HRAS CDKN2A
10
Show member pathways
11.93 TP53 KRAS HRAS EGFR
11 11.87 TP53 KRAS HRAS CDKN2A
12 11.58 TP53 KRAS HRAS
13 11.57 TP53 KRAS HRAS EGFR
14 11.5 KRAS HRAS EGFR
15 11.48 TP53 MGMT KRAS HRAS EGFR CDKN2A
16 11.44 TP53 EGFR CDKN2A
17 11.35 NQO1 KRAS HRAS EGFR
18 11.33 KRAS HRAS EGFR
19 11.15 KRAS HRAS EGFR
20 11.08 RASSF1 KRAS EGFR
21
Show member pathways
11.05 KRAS HRAS EGFR
22 10.96 TP53 RASSF1 KRAS HRAS EGFR CDKN2A

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.8 NCAM1 KRAS HRAS EGFR
2 positive regulation of gene expression GO:0010628 9.8 TP53 NKX2-1 KRAS HRAS CDKN2A
3 liver development GO:0001889 9.65 RARB KRAS EGFR
4 positive regulation of MAP kinase activity GO:0043406 9.54 KRAS HRAS EGFR
5 cerebral cortex cell migration GO:0021795 9.46 NKX2-1 EGFR
6 cell cycle arrest GO:0007050 9.46 TP53 RASSF1 HRAS CDKN2A
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR
8 response to isolation stress GO:0035900 9.32 KRAS HRAS
9 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.26 GRP CHGA
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.13 SYP KRAS HRAS
11 Ras protein signal transduction GO:0007265 9.02 TP53 RASSF1 KRAS HRAS CDKN2A

Sources for Lung Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....